D K R Colorado B I O 07 Final

583 views

Published on

Published in: Business, Sports
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
583
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
4
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

D K R Colorado B I O 07 Final

  1. 1. Challenges and Opportunities for Growth and Innovation in Pharmaceuticals and Biotechnology Colorado’s Bioscience Community: Building on the Foundation August 28, 2007 David K. Rosen, D.V.M. Head, Development and Commercial Strategic Alliances Pfizer Inc
  2. 2. Pfizer is an Innovative, Global Research- Based Health Care Company Products Category Lipid-Lowering Hypertension/Angina Arthritis Depression/Anxiety Antibiotic Erectile Dysfunction Lyrica Fibromyalgia Antifungal 2
  3. 3. Therapeutic Area Strategy How it Works in Pfizer PURSUE AGGRESSIVELY – Increase investment to ensure success  Risk: Multiple shots on goal to offset risk  Speed: Invest for speed STANDARD – Current Pfizer approach to drug development ALTRUISTIC – Targeted investment to address social need STAGED INVESTMENT  Technical Doability: Develop the science  Commercial Doability: More market research to understand the opportunity MONITOR – Do not invest until technical or commercial opportunity clarifies EXIT – No further investment in this area 3
  4. 4. Pharmaceutical Industry Challenges 4
  5. 5. Pfizer Conducts R&D Globally Cambridge, MA Sandwich, La Jolla, CA ENGLAND St. Louis, New London Exiting: MO & Groton,CT •Kalamazoo, MI •Ann Arbor, MI •Nagoya , Japan 5
  6. 6. Shrinking Market Exclusivity Innovative Drug / 2nd Generation Year Introduced Drug/Year Inderal - 1965 Lopressor - 1978 Tagamet - 1977 Zantac - 1983 Capoten - 1980 Vasotec - 1985 Seldane - 1985 Hismanal – 1989 AZT - 1987 Videx – 1991 Mevacor - 1987 Pravachol – 1991 Prozac - 1988 Zoloft – 1992 Diflucan - 1990 Sporonox – 1992 Recombinate - 1992 Kogenate – 1992 Celebrex - 1999 Vioxx– 1999 0 1 2 3 4 5 6 7 8 9 10 Years of Exclusivity for Innovative Drug 6
  7. 7. High Attrition Rate in Drug Development Thousands of Compounds Screened ~100 Discovery Approaches High Risk Process Preclinical Pharmacology ~250 12-15 years, ~$1 B/candidate Preclinical Safety ~5 1 –2 Products Clinical Pharmacology & Safety Discovery Exploratory Development Full Development Phase I Phase II Phase III 0 5 10 15 Idea 11 - 15 Years Drug 7
  8. 8. Expanding the Scope of R&D Future Biologics Powerhouse (pegvisomant for injection) human insulin powder (interferon beta-1a) (dalteparin sodium injection) PEG-hGH CTLA4 mAb MCSF mAb ETC-588 TLR CPG 7909 ETC-216 T2-TrpRS IGF1R mAb ETC-642 CD40 mAb MAdCAM mAb $1.5 Billion Pfizer 2006 Biologics Sales 8 NY 7/31/2006
  9. 9. Non-Invasive Protein Delivery  Exubera®: The first inhaled insulin  A breakthrough in diabetes treatment 9
  10. 10. Biomarkers, Diagnostics and Devices  Pfizer is interested seeing these biomarkers, diagnostics and devices developed and commercialized but our role is enabling  Our interest is in access to the technology for R&D; results and data  How will we use these technologies?  Designing medicines  Monitoring disease  Identifying patients who will respond to a medicine  Identifying patients who might respond adversely to a medicine 10
  11. 11. Data Management  Our needs extend beyond what would traditionally be seen or considered as science  Applications like medical records are obvious  What else do we need to do or want to do with this data?  Data acquisition  Data mining  Data analysis  Data exchange and meta-analysis – clinical trials – diagnostics and genetic testing 11
  12. 12. Precompetitive and Competitive Technologies an Alzheimer’s Disease Example  Precompetitive Technology:  We all need better (more accurate at an earlier stage of disease), faster, less expensive ways to diagnose AD  Help us enroll patients in clinical trials with confirmed AD  Determine if drug was having impact on disease progression  Fund as a consortium?  Competitive Technology  An AD diagnostic customized for our compound which would allow us to compare how our drug is impacting the patient as compared with similar therapies  Fund on our own 12
  13. 13. Productivity Challenge $40 $35 Total R&D Investment ($Billions) $30 $25 $20 $15 $10 $5 $0 2005 2000 1985 1990 1995 1970 1975 1980 13 Source: 2006 PhRMA Annual Survey
  14. 14. Total BioPharmaceutical R&D Spending 2005-2006 ($Billions) $55 Total spending increased by $3.4 B Biotech $50 From 2005 to 2006 20% $45 $40 $35 $30 $25 Pharma $20 80% $15 $10 $5 $0 2005 1995 2000 1970 1985 1990 1975 1980 14 Source: 2006 PhRMA Annual Survey
  15. 15. Staying Competitive in a Changing Global Environment: Pfizer’s evolving strategy  Technical expertise is available around the globe  India has chemistry innovation  China has chemistry innovation and clinical trial capacity  South Korea has advanced data collection and transmission, patient monitoring and clinical trial capacity and implementation  All of these countries have scientific and technical experts educated in the west and trained at the top 20 pharmaceutical companies in the west 15
  16. 16. Opportunities for Growth and Innovation
  17. 17. We are one of the leading source of Biotech funding Industry leading investment in R&D $7.7 $7.5 $7.5 $7.1  Total Strategic Alliances Spending: >$1.4B in the last 4 ($Billions) years $5.2 $4.8 $4.4  “Pfizer…the largest source of discovery stage biotech capital” Source: In Vivo, September 2004 $2.3 $2.3 $1.8 $1.6 1996 1998 2000 2002 2004 2006 Source: Pfizer Annual Report 17
  18. 18. Extensive External Reach  2006: Over 1800 business transactions/ >800 collaborations  Global organization of 56 people at 6 sites in US/EU/AustralAsia - predominantly scientific expertise with enhancements:  Finance, Business, Law, Medicine, Marketing/Sales, M&A  Global colleague interaction allows synergistic expertise  Strategic Alliances presently covers all areas of Research and Development including deals/technologies that interface with Manufacturing, Veterinary Medicine, PGP, and Consumer Health Care 18
  19. 19. Agreement Types  Non-disclosure agreement  Material transfer agreement  License to patent/intellectual property  Research collaboration  Corporate collaboration (major deal)  Consultantship  Fee for service (outsourcing contracts)  Acquisition of new chemical entities 19
  20. 20. Alliance Types  Research – Genes, Leads, Targets, Technology (Scripps)  Candidate Producing (Kosan, ICAgen)  In-Licensing – Early & Late Stage (Renovis, TransTech)  Out-licensing – Assets, IP, Patents, Niche products (Darafenicin)  Joint Venture – Marketing for Products (Insulin production)  Co-promotion Deals – Risk & Reward (Rebif)  M&A – Pipeline, Resources, Financial, Strategic (Rinat, Powdermed) 20
  21. 21. Pfizer Global Research and Development Major Alliance Partnerships: March 2006 Speeding/Enhancing Altering the R&D Enhancing Development Productivity Paradigm Pipeline Value Candidates Product Gene Function Screen Lead Candidate Development Speed Enhancement Athersys Affymetrix Biotrove Amgen Neurion Amersham U. Michigan Alza Chondrogene Deltagen Evotec Cerep Vicuron (acqu) U. Cambridge ProModel Atrix (QTL) Metabolex InPharmatica Stem Cell Sci Entelos Wake Forest Curagen Genestruct Ventaira Karolinska Xenogen U. Dundee Spotfire Monogram GeneLogic Codexis Bend U. Pittsburgh Lexicon Gen Xenoport Medarex Rigel Lonza Perlegen Nektar Wash. U Chondrogene Lilly Morphosys Nicox Meridica (acq) Lifespan Freie Univ. Cerep ActivX Quorex Angiosyn Kings Pain Ctr Genizon U. Rochester Perlegen/NIH Sangamo Isis Idun (acqu) NIA Oxford Scripps Odyssey Th. TRansTech Coley Virtual Scopics Biosensors Archimex Renovis Yale Noxxon Symyx GeneLogic Boehringer Ingelheim Chromos iCardiac 21
  22. 22. How will Pfizer Invest in New Technologies in 2007 and Beyond? Strategic themes for SA investments Productivity  CAN producing alliances  TA Enablers- focused alliances  Emerging science/technologies investments Leveraging Scale  Cross-line technology investments  Technologies enhancing Speed/Efficiency/Process Flexible Budget Emerging Sciences Periodic review of where SPEED/Efficiency/Process TAPT Enablers we are investing CAN-producing alliances 22
  23. 23. Investing In The Future  Gene Therapy  Therapeutic Vaccines  Biomarkers, Diagnostics and Personalized Medicine  Data Management  Pfizer’s Incubator 23 NY 7/31/2006
  24. 24. Pfizer Strategic Alliances Thank you 24

×